港股異動 | 大肆分化!新華製藥H股跌幅擴大至超21% A股9連板創新高
格隆匯5月11日丨新華製藥H股午後跌幅持續擴大,現大跌21.25%,然而A股已連續9個交易日漲停,今日再度刷新歷史新高。4月26日,真實生物與新華製藥達成戰略合作協議。AH股攜手開啟大漲行情,但公司在5月9日晚間異常波動公吿中指出,合作雙方達成的只是初步戰略性合作協議,目前尚未簽署任何相關產品的具體合作協議,並且該戰略合作協議並無排他性,新華製藥並非真實生物的唯一合作方。此外,在研發國產新冠口服藥的公司,不止真實生物一家,君實生物的新冠口服藥也處於國際多中心的III期臨牀研究階段。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.